© 2022 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
Play Live Radio
Next Up:
0:00
0:00
Available On Air Stations

Will Low-Nicotine Cigarettes Stop People From Smoking? Yale Prof Says Answer Is Not Clear

1280px-Marlboro4wiki2.JPG
Nikita2706
/
Wikimedia Commons

For the first time in its history, the Food and Drug Administration has announced it’s looking at ways to reduce nicotine in cigarettes to non-addictive levels.

The FDA has broad authority to regulate nicotine, particularly in smoked cigarettes, says Marina Picciotto. She's the Charles B. G. Murphy professor of psychiatry at Yale University, and has researched nicotine and its effect on human behavior.

I spoke with Picciotto about this approach to curb smoking addiction.

She said the FDA’s proposal centers on human studies that have shown that if you lower the nicotine content below a certain threshold, people will just stop smoking cigarettes on their own.

"That’s because we know that the nicotine in tobacco is the primary ingredient that results in addiction and that causes people to keep smoking,” Picciotto said. “So there have been a number of controlled clinical studies that have offered ongoing smokers these very low-nicotine cigarettes, and they’ve found that they can identify a level below which people will stop smoking. And that’s about .5 milligrams per cigarette."

WNPR’s Diane Orson: So does this idea make sense to you?

Marina Picciotto: Well, it only makes sense if there are not other options for smokers. The truth is that an addicted smoker who does not choose to quit, who does not want to quit, will continue to seek nicotine. And so if the available commercial products have too little nicotine for a smoker, they may go to the black market. They may find online ways to seek foreign cigarettes.

What I do think is very specific to nicotine and tobacco is that there are a wide variety of reasons that people smoke. It is clear that nicotine is addictive. People also report that they smoke for other reasons. For example, people say that they will smoke before they do a difficult task because it focuses their attention. Or particularly among adolescents, they’ll say that they will smoke to control their appetite. And finally, people have suggested that they smoke to control their symptoms of anxiety and depression.

So if you add to the addictive potential of nicotine, all of these other psychoactive effects of nicotine, then you see that people smoke cigarettes for so many reasons, that it makes it extra hard to quit.

Is it nicotine alone that causes the addiction, or is it somehow the interaction between nicotine and the other stuff in cigarettes?

That’s a great question, and there have been many studies that suggest that there are additional components in tobacco smoke that enhance the addictive effects of nicotine.

What about e-cigarettes?

E-cigarettes are interesting, because they should be a method of delivering nicotine that does not include some of the other components of tobacco smoke that we know are carcinogens. But we still don’t know what the effect of just nicotine alone, or the other constituent flavors -- menthol, the carrier for nicotine -- will do to human health. This is an experiment that we’re doing on ourselves.

It took many decades for us to realize that cigarette smoking was a very serious public health hazard. And so now, we are all subjecting ourselves to a very long-term experiment. And we’ll find out, probably in a few decades, whether there are more or less public health consequences of the huge uptick of e-cigarette use.

Getting back to the FDA proposal: What happens now?

Well, I think the next thing that happens is that there are series of hearings. The FDA is required to use published studies and scientific evidence to generate its rules, and to make decisions. So I would imagine that they would form a scientific panel to investigate the scientific evidence behind this choice, and that there would then be hearings on proposed regulations.

Diane Orson is a special correspondent with Connecticut Public. She is a longtime reporter and contributor to National Public Radio. Her stories have been heard on Morning Edition, All Things Considered, Weekend Edition and Here And Now. Diane spent seven years as CT Public Radio's local host for Morning Edition.
Related Content
  • Connecticut has received an initial installment of $11 million from a $26 billion multistate settlement with Johnson & Johnson and drug wholesalers AmerisourceBergen, Cardinal Health, and McKesson. The four drug companies were sued for their roles in the opioid crisis. Over the next 18 years, Connecticut will receive $300 million as part of the settlement reached in February. Connecticut Attorney General William Tong announced the first payment in Waterbury on Monday. He was joined by state officials and also parents who lost children to the opioid crisis.
  • Xylazine is not approved for humans. But it's being found in a quarter of drug samples tested statewide in Massachusetts. The sedative is linked to severe wounds, extreme anxiety in withdrawal, more overdoses and possibly more deaths.
  • Over 300 people have been awarded the Ig Nobel Prize for making people laugh and then think. On this episode of Audacious, meet the creator of the prize, and three people who’ve won it!